|
Report No. : |
351364 |
|
Report Date : |
04.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
EMCURE PHARMACEUTICALS SINGAPORE PTE. LTD. |
|
|
|
|
Registered Office : |
1, Raffles Place, 29-02, One Raffles Place, 048616 |
|
|
|
|
Country : |
Singapore |
|
|
|
|
Financials (as on) : |
31.03.2014 |
|
|
|
|
Date of Incorporation : |
13.12.2012 |
|
|
|
|
Com. Reg. No.: |
201230556-G |
|
|
|
|
Legal Form : |
Private Limited |
|
|
|
|
Line of Business : |
Doormat |
|
|
|
|
No. of Employee : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
C |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
Status : |
Dissolved |
|
|
|
|
Payment Behaviour : |
-- |
|
|
|
|
Litigation : |
-- |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Singapore |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SINGAPORE - ECONOMIC OVERVIEW
Singapore has a highly developed and successful free-market economy. It enjoys a remarkably open and corruption-free environment, stable prices, and a per capita GDP higher than that of most developed countries. Unemployment is very low. The economy depends heavily on exports, particularly of consumer electronics, information technology products, medical and optical devices, pharmaceuticals, and on its vibrant transportation, business, and financial services sectors. The economy contracted 0.6% in 2009 as a result of the global financial crisis, but has continued to grow since 2010 on the strength of renewed exports. Growth in 2014 was slower at 2.9%, largely a result of soft demand for exports amid a sluggish global economy and weak growth in Singapore’s manufacturing sector. The government is attempting to restructure Singapore’s economy by weaning its dependence on foreign labor, addressing weak productivity, and increasing Singaporean wages. Singapore has attracted major investments in pharmaceuticals and medical technology production and will continue efforts to strengthen its position as Southeast Asia's leading financial and high-tech hub. Singapore is a member of the 12-nation Trans-Pacific Partnership free trade negotiations, the Regional Comprehensive Economic Partnership negotiations with the nine other ASEAN members plus Australia, China, India, Japan, South Korea and New Zealand, and in 2015, Singapore will form, with the other ASEAN members, the ASEAN Economic Community.
|
Source
: CIA |
|
REGISTRATION
NO. |
: |
201230556-G |
|
COMPANY
NAME |
: |
EMCURE
PHARMACEUTICALS SINGAPORE PTE. LTD. |
|
FORMER
NAME |
: |
N/A |
|
INCORPORATION
DATE |
: |
13/12/2012 |
|
COMPANY
STATUS |
: |
DISOLVED
(13/10/2015) |
|
LEGAL
FORM |
: |
PRIVATE
LIMITED |
|
LISTED
STATUS |
: |
NO |
|
REGISTERED
ADDRESS |
: |
1,
RAFFLES PLACE, 29-02, ONE RAFFLES PLACE, 048616, SINGAPORE. |
|
BUSINESS
ADDRESS |
: |
N/A |
|
TEL.NO. |
: |
N/A |
|
FAX.NO. |
: |
N/A |
|
CONTACT
PERSON |
: |
N/A |
|
PRINCIPAL
ACTIVITY |
: |
DORMANT |
|
ISSUED
AND PAID UP CAPITAL |
: |
50,000.00
ORDINARY SHARE, OF A VALUE OF SGD 50,000.00 |
|
SALES |
: |
N/A |
|
NET
WORTH |
: |
SGD
26,367 [2014] |
|
STAFF
STRENGTH |
: |
N/A |
|
LITIGATION |
: |
CLEAR |
|
FINANCIAL
CONDITION |
: |
N/A |
|
PAYMENT |
: |
N/A |
|
MANAGEMENT
CAPABILITY |
: |
N/A |
|
COMMERCIAL
RISK |
: |
N/A |
|
CURRENCY
EXPOSURE |
: |
N/A |
|
GENERAL
REPUTATION |
: |
N/A |
|
INDUSTRY
OUTLOOK |
: |
NOT
YET DETERMINED |
The Subject is a private limited company and is
allowed to have a minimum of one and a maximum of forty-nine shareholders. As a
private limited company, the Subject must have at least two directors. A
private limited company is a separate legal entity from its shareholders. As a
separate legal entity, the Subject is capable of owning assets, entering into
contracts, sue or be sued by other companies. The liabilities of the
shareholders are to the extent of the equity they have taken up and the
creditors cannot claim on shareholders' personal assets even if the Subject is
insolvent. The Subject is governed by the Companies Act and the company must
file its annual returns, together with its financial statements with the
Registrar of Companies.
The
Subject is principally engaged in the (as a / as an) dormant.
Share
Capital History
|
Date |
Issue
& Paid Up Capital |
|
03/12/2015 |
SGD
50,000.00 |
The
major shareholder(s) of the Subject are shown as follows :
Current
Shareholder(s) :
|
Name |
Address |
IC/PP/Loc
No |
Shareholding |
(%) |
|
EMCURE
PHARMACEUTICALS LIMITED |
"EMCURE
HOUSE" T-184,M.I.D.C. BHOSARI, PUNE 411026, MAHARASHTRA |
T12UF4697 |
50,000.00 |
100.00 |
|
--------------- |
------ |
|||
|
50,000.00 |
100.00 |
|||
|
============ |
===== |
+
Also Director
DIRECTOR
1
|
Name
Of Subject |
: |
ARUN
KUMAR KHANNA |
|
Address |
: |
63,
CLOVER HILLS, NIBM ROAD, KONDHWA, PUNE 411048, MAHARASHTRA, INDIA. |
|
IC
/ PP No |
: |
Z2438381 |
|
Nationality |
: |
INDIAN |
|
Date
of Appointment |
: |
13/12/2012 |
DIRECTOR
2
|
Name
Of Subject |
: |
VIKAS
THAPAR |
|
Address |
: |
A-14,
MARIGOLD COMPLEX, PHASE I, CO-OPERATIVE HOUSING SOCIETY, PUNE 411004,
MAHARASHTRA, INDIA. |
|
IC
/ PP No |
: |
422067966 |
|
Nationality |
: |
AMERICAN |
|
Date
of Appointment |
: |
13/12/2012 |
DIRECTOR
3
|
Name
Of Subject |
: |
TARIQ
SYED USMAN |
|
Address |
: |
3,
SIMEI STREET 3, 08-10, EASTPOINT GREEN, 529891, SINGAPORE. |
|
IC
/ PP No |
: |
G5941138T |
|
Nationality |
: |
PAKISTANI |
|
Date
of Appointment |
: |
01/12/2014 |
No data found in our databank.
|
Auditor |
: |
HELMI
TALIB & CO |
|
Auditor'
Address |
: |
N/A |
|
1) |
Company
Secretary |
: |
CAROLINE
BAKER |
|
IC
/ PP No |
: |
G5327533N |
|
|
Address |
: |
2,
MARINA BOULEVARD, 03-05, THE SAIL @ MARINA BAY, 018987, SINGAPORE. |
|
No Banker found in our databank.
No encumbrance was found in our databank at the time of investigation.
* A check has been conducted in our databank againt the Subject whether the
subject has been involved in any litigation.
No legal action was found in our databank.
No winding up petition was found in our databank.
|
SOURCES
OF RAW MATERIALS: |
||
|
Local |
: |
N/A |
|
Overseas |
: |
N/A |
|
Local |
: |
N/A |
|
Overseas |
: |
N/A |
|
Branch |
: |
NO |
Other
Information:
The Subject is principally engaged in the (as a / as an) dormant.
Latest
fresh investigations carried out on the Subject indicated that :
|
Telephone
Number Provided By Client |
: |
N/A |
|
Current
Telephone Number |
: |
N/A |
|
Match |
: |
N/A |
|
Address
Provided by Client |
: |
SINGAPORE |
|
Current
Address |
: |
N/A |
|
Match |
: |
N/A |
Other
Investigations
We were unable to contact the Subject and its Directors.
Based on the registry, the Subject had already been disolved.
|
The
Subject is a dormant company. Thus it is not appropriate for us to comment on
the Subject's financial performance. |
||||||
|
Overall
financial condition of the Subject : N/A |
||||||
|
Major
Economic Indicators : |
2010 |
2011 |
2012 |
2013 |
2014 |
|
|
|||||
|
Population
(Million) |
5.08 |
5.18 |
5.31 |
5.40 |
5.47 |
|
Gross
Domestic Products ( % ) |
14.5 |
4.9 |
1.3 |
3.7 |
(3.5) |
|
Consumer
Price Index |
2.8 |
5.2 |
4.6 |
2.4 |
2.4 |
|
Total
Imports (Million) |
423,221.8 |
459,655.1 |
474,554.0 |
466,762.0 |
463,779.1 |
|
Total
Exports (Million) |
478,840.7 |
514,741.2 |
510,329.0 |
513,391.0 |
518,922.7 |
|
|
|||||
|
Unemployment
Rate (%) |
2.2 |
2.1 |
2.0 |
1.9 |
1.9 |
|
Tourist
Arrival (Million) |
11.64 |
13.17 |
14.49 |
15.46 |
15.01 |
|
Hotel
Occupancy Rate (%) |
85.6 |
86.5 |
86.4 |
86.3 |
85.5 |
|
Cellular
Phone Subscriber (Million) |
1.43 |
1.50 |
1.52 |
1.97 |
1.98 |
|
|
|||||
|
Registration
of New Companies (No.) |
29,798 |
32,317 |
31,892 |
37,288 |
41,589 |
|
Registration
of New Companies (%) |
12.8 |
8.5 |
(1.3) |
9.8 |
11.5 |
|
Liquidation
of Companies (No.) |
15,126 |
19,005 |
17,218 |
17,369 |
18,767 |
|
Liquidation
of Companies (%) |
(32.5) |
25.6 |
9.4 |
(5.3) |
8.0 |
|
|
|||||
|
Registration
of New Businesses (No.) |
23,978 |
23,494 |
24,788 |
22,893 |
35,773 |
|
Registration
of New Businesses (%) |
(10.78) |
2.02 |
5.51 |
1.70 |
56.30 |
|
Liquidation
of Businesses (No.) |
24,211 |
23,005 |
22,489 |
22,598 |
22,098 |
|
Liquidation
of Businesses (%) |
2.8 |
(5) |
(2.2) |
0.5 |
(2.2) |
|
|
|||||
|
Bankruptcy
Orders (No.) |
1,537 |
1,527 |
1,748 |
1,992 |
1,757 |
|
Bankruptcy
Orders (%) |
(25.3) |
(0.7) |
14.5 |
14.0 |
(11.8) |
|
Bankruptcy
Discharges (No.) |
2,252 |
1,391 |
1,881 |
2,584 |
3,546 |
|
Bankruptcy
Discharges (%) |
(26.3) |
(38.2) |
35.2 |
37.4 |
37.2 |
|
|
|||||
|
INDUSTRIES
( % of Growth ) : |
|||||
|
Agriculture |
|||||
|
Production
of Principal Crops |
(0.48) |
4.25 |
3.64 |
- |
|
|
Fish
Supply & Wholesale |
(10.5) |
12.10 |
(0.5) |
- |
2.80 |
|
|
|||||
|
Manufacturing
* |
92.8 |
100.0 |
100.3 |
102.0 |
|
|
Food,
Beverages & Tobacco |
96.4 |
100.0 |
103.5 |
103.5 |
105.0 |
|
Textiles |
122.1 |
100.0 |
104.0 |
87.1 |
74.9 |
|
Wearing
Apparel |
123.3 |
100.0 |
92.1 |
77.8 |
49.5 |
|
Leather
Products & Footwear |
81.8 |
100.0 |
98.6 |
109.8 |
95.9 |
|
Wood
& Wood Products |
104.0 |
100.0 |
95.5 |
107.4 |
112.0 |
|
Paper
& Paper Products |
106.1 |
100.0 |
97.4 |
103.2 |
103.4 |
|
Printing
& Media |
103.5 |
100.0 |
93.0 |
86.1 |
80.3 |
|
Crude
Oil Refineries |
95.6 |
100.0 |
99.4 |
93.5 |
85.6 |
|
Chemical
& Chemical Products |
97.6 |
100.0 |
100.5 |
104.1 |
114.0 |
|
Pharmaceutical
Products |
75.3 |
100.0 |
109.7 |
107.2 |
115.7 |
|
Rubber
& Plastic Products |
112.3 |
100.0 |
96.5 |
92.9 |
92.8 |
|
Non-metallic
Mineral |
92.5 |
100.0 |
98.2 |
97.6 |
82.2 |
|
Basic
Metals |
102.2 |
100.0 |
90.6 |
76.5 |
98.3 |
|
Fabricated
Metal Products |
103.6 |
100.0 |
104.3 |
105.1 |
105.1 |
|
Machinery
& Equipment |
78.5 |
100.0 |
112.9 |
114.5 |
124.0 |
|
Electrical
Machinery |
124.1 |
100.0 |
99.3 |
108.5 |
121.3 |
|
Electronic
Components |
113.6 |
100.0 |
90.6 |
94.3 |
95.0 |
|
Transport
Equipment |
94.0 |
100.0 |
106.3 |
107.5 |
103.2 |
|
|
|||||
|
Construction |
14.20 |
20.50 |
28.70 |
- |
22.00 |
|
Real
Estate |
21.3 |
25.4 |
31.9 |
- |
145.1 |
|
|
|||||
|
Services |
|||||
|
Electricity,
Gas & Water |
4.00 |
7.00 |
6.30 |
- |
|
|
Transport,
Storage & Communication |
12.80 |
7.40 |
5.30 |
- |
14.20 |
|
Finance
& Insurance |
(0.4) |
8.90 |
0.50 |
- |
6.00 |
|
Government
Services |
9.70 |
6.90 |
6.00 |
- |
|
|
Education
Services |
(0.9) |
(1.4) |
0.30 |
- |
5.98 |
|
|
|||||
|
*
Based on Index of Industrial Production (2011 = 100) |
|
INDUSTRY
: |
DORMANT |
|
The
Subject is a dormant company and it is not active in its business operation. |
|
|
OVERALL
INDUSTRY OUTLOOK : NOT YET DETERMINED |
|
|
As
the Subject is a dormant company, it is inappropriate to comment on its
creditworthiness. In view of the above, we do not recommend any credit be
granted to the Subject. |
|
THE
FINANCIAL STATEMENTS WERE PREPARED IN ACCORDANCE WITH SINGAPORE FINANCIAL
REPORTING STANDARDS. |
|
EMCURE
PHARMACEUTICALS SINGAPORE PTE. LTD. |
|
Financial
Year End |
2014-03-31 |
2013-03-31 |
|
Months |
12 |
12 |
|
Consolidated
Account |
Company |
Company |
|
Audited
Account |
YES |
YES |
|
Unqualified
Auditor's Report (Clean Opinion) |
YES |
YES |
|
Financial
Type |
FULL |
FULL |
|
Currency |
SGD |
SGD |
|
PROFIT/(LOSS)
FROM OPERATIONS |
(18,200) |
(5,433) |
|
---------------- |
---------------- |
|
|
PROFIT/(LOSS)
BEFORE TAXATION |
(18,200) |
(5,433) |
|
---------------- |
---------------- |
|
|
PROFIT/(LOSS)
AFTER TAXATION |
(18,200) |
(5,433) |
|
---------------- |
---------------- |
|
|
RETAINED
PROFIT/(LOSS) BROUGHT FORWARD |
||
|
As
previously reported |
(5,433) |
- |
|
---------------- |
---------------- |
|
|
As
restated |
(5,433) |
- |
|
---------------- |
---------------- |
|
|
PROFIT
AVAILABLE FOR APPROPRIATIONS |
(23,633) |
(5,433) |
|
---------------- |
---------------- |
|
|
RETAINED
PROFIT/(LOSS) CARRIED FORWARD |
(23,633) |
(5,433) |
|
============= |
============= |
|
|
EMCURE PHARMACEUTICALS SINGAPORE
PTE. LTD. |
|
Other
debtors, deposits & prepayments |
5,587 |
15,588 |
|
Amount
due from holding company |
- |
250,000 |
|
Cash
& bank balances |
27,984 |
50,000 |
|
---------------- |
---------------- |
|
|
TOTAL
CURRENT ASSETS |
33,571 |
315,588 |
|
---------------- |
---------------- |
|
|
TOTAL
ASSET |
33,571 |
315,588 |
|
============= |
============= |
|
|
Other
creditors & accruals |
7,204 |
21,021 |
|
---------------- |
---------------- |
|
|
TOTAL
CURRENT LIABILITIES |
7,204 |
21,021 |
|
---------------- |
---------------- |
|
|
NET
CURRENT ASSETS/(LIABILITIES) |
26,367 |
294,567 |
|
---------------- |
---------------- |
|
|
TOTAL
NET ASSETS |
26,367 |
294,567 |
|
============= |
============= |
|
|
SHARE
CAPITAL |
||
|
Ordinary
share capital |
50,000 |
300,000 |
|
---------------- |
---------------- |
|
|
TOTAL
SHARE CAPITAL |
50,000 |
300,000 |
|
Retained
profit/(loss) carried forward |
(23,633) |
(5,433) |
|
---------------- |
---------------- |
|
|
TOTAL
RESERVES |
(23,633) |
(5,433) |
|
---------------- |
---------------- |
|
|
SHAREHOLDERS'
FUNDS/EQUITY |
26,367 |
294,567 |
|
---------------- |
---------------- |
|
|
26,367 |
294,567 |
|
|
============= |
============= |
|
|
EMCURE
PHARMACEUTICALS SINGAPORE PTE. LTD. |
|
TYPES
OF FUNDS |
||
|
Cash |
27,984 |
50,000 |
|
Net
Liquid Funds |
27,984 |
50,000 |
|
Net
Liquid Assets |
26,367 |
294,567 |
|
Net
Current Assets/(Liabilities) |
26,367 |
294,567 |
|
Net
Tangible Assets |
26,367 |
294,567 |
|
Net
Monetary Assets |
26,367 |
294,567 |
|
PROFIT
& LOSS ITEMS |
||
|
Earnings
Before Interest & Tax (EBIT) |
(18,200) |
(5,433) |
|
Earnings
Before Interest, Taxes, Depreciation And Amortization (EBITDA) |
(18,200) |
(5,433) |
|
BALANCE
SHEET ITEMS |
||
|
Total
Borrowings |
0 |
0 |
|
Total
Liabilities |
7,204 |
21,021 |
|
Total
Assets |
33,571 |
315,588 |
|
Net
Assets |
26,367 |
294,567 |
|
Net
Assets Backing |
26,367 |
294,567 |
|
Shareholders'
Funds |
26,367 |
294,567 |
|
Total
Share Capital |
50,000 |
300,000 |
|
Total
Reserves |
(23,633) |
(5,433) |
|
LIQUIDITY
(Times) |
||
|
Cash
Ratio |
3.88 |
2.38 |
|
Liquid
Ratio |
4.66 |
15.01 |
|
Current
Ratio |
4.66 |
15.01 |
|
WORKING
CAPITAL CONTROL (Days) |
||
|
Stock
Ratio |
0 |
0 |
|
Debtors
Ratio |
0 |
0 |
|
Creditors
Ratio |
0 |
0 |
|
SOLVENCY
RATIOS (Times) |
||
|
Gearing
Ratio |
0 |
0 |
|
Liabilities
Ratio |
0.27 |
0.07 |
|
Times
Interest Earned Ratio |
0 |
0 |
|
Assets
Backing Ratio |
0.53 |
0.98 |
|
PERFORMANCE
RATIO (%) |
||
|
Operating
Profit Margin |
0 |
0 |
|
Net
Profit Margin |
0 |
0 |
|
Return
On Net Assets |
(69.03) |
(1.84) |
|
Return
On Capital Employed |
(69.03) |
(1.84) |
|
Return
On Shareholders' Funds/Equity |
(69.03) |
(1.84) |
|
Dividend
Pay Out Ratio (Times) |
0 |
0 |
|
NOTES
TO ACCOUNTS |
||
|
Contingent
Liabilities |
0 |
0 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.351364 |
|
|
1 |
Rs.99.61 |
|
Euro |
1 |
Rs.70.67 |
|
SGD |
1 |
Rs. 47.86 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
ASH |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.